class="wp-theme-Newspaper supp-body td-standard-pack global-block-template-1 tdc-header-template tdc-footer-template td-animation-stack-type0 td-full-layout"
HORMONE-SENSITIVE CANCERS: Contraindicated in ER+ breast cancer — conflicting data; some studies show proliferative effects in some ER+ cell lines. Endometrial cancer, uterine fibroids, endometriosis: AVOID. Thyroid: inhibits thyroid peroxidase — avoid in hypothyroidism or take separately from thyroid medication. Drug interactions: tamoxifen. Male: may reduce testosterone at high doses. Pregnancy: phytooestrogenic effects.
Most abundant and biologically active soy isoflavone — phytoestrogen with binding affinity for oestrogen receptors ERα and ERβ. Inhibits tyrosine kinases and topoisomerase II. Studied for cancer prevention, bone health, menopausal symptoms, and cardiovascular risk. More potent oestrogenic activity than daidzein.
Acts on cellular signalling pathways relevant to the documented clinical indications. Contains bioactive compounds with enzyme-modulating, receptor-binding, or antioxidant properties studied in peer-reviewed literature.
| Population | Safety rating | Max safe dose |
|---|---|---|
| General | Possibly unsafe | — |
| Pregnancy | Possibly unsafe | — |
| Elderly | Possibly unsafe | — |
No peer-reviewed clinical trial data found for this ingredient.
Data by supplement.ge — Public Health Institute of Georgia (PHIG)